RT Journal Article
SR Electronic
T1 The emergence of COVID-19 in Indonesia: analysis of predictors of infection and mortality using independent and clustered data approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.10.20147942
DO 10.1101/2020.07.10.20147942
A1 Burhan, Erlina
A1 Syam, Ari Fahrial
A1 Rahyussalim, Ahmad Jabir
A1 Prasenohadi,
A1 Wulung, Navy G Lolong
A1 Susanto, Agus Dwi
A1 Ketut Sajinadiyasa, I Gede
A1 Puspitorini, Dewi
A1 Lestari, Dewi
A1 Widyahening, Indah Suci
A1 Setiawaty, Vivi
A1 Ocviyanti, Dwiana
A1 Putri, Kartika Qonita
A1 Guntara, Aswin
A1 Rianda, Davrina
A1 Shankar, Anuraj H
A1 Agustina, Rina
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.10.20147942.abstract
AB Background Analyses of correlates of SARS-CoV-2 infection or mortality have usually assessed individual predictors. This study aimed to determine if patterns of combined predictors may better identify risk of infection and mortalityMethods For the period of March 2nd to 10th 2020, the first 9 days of the COVID-19 pandemic in Indonesia, we selected all 18 confirmed cases, of which 6 died, and all 60 suspected cases, of which 1 died; and 28 putatively negative patients with pneumonia and no travel history. We recorded data for travel, contact history, symptoms, haematology, comorbidities, and chest x-ray. Hierarchical cluster analyses (HCA) and principal component analyses (PCA) identified cluster and covariance patterns for symptoms or haematology which were analysed with other predictors of infection or mortality using logistic regression.Results For univariate analyses, no significant association with infection was seen for fever, cough, dyspnoea, headache, runny nose, sore throat, gastrointestinal complaints (GIC), or haematology. A PCA symptom component for fever, cough, and GIC tended to increase risk of infection (OR 3.41; 95% CI 1.06-14; p=0.06), and a haematology component with elevated monocytes decreased risk (OR 0.26; 0.07-0.79; 0.027). Multivariate analysis revealed that an HCA cluster of 3-5 symptoms, typically fever, cough, headache, runny nose, sore throat but little dyspnoea and no GIC tended to reduce risk (aOR 0.048; <0.001–0.52; 0.056). In univariate analyses for death, an HCA cluster of cough, fever and dyspnoea had increased risk (OR 5.75; 1.06 − 31.3, 0.043), but no other individual predictor, cluster or component was associated. Other significant predictors of infection were age ≥ 45, international travel, contact with COVID-19 patient, and pneumonia. Diabetes and history of contact were associated with higher mortality.Conclusions Cluster groups and co-variance patterns may be stronger correlates of SARS-CoV-2 infection than individual predictors. Comorbidities may warrant careful attention as would COVID-19 exposure levels.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grant award from the Directorate Research and Community Services Universitas Indonesia (PUTI Q1) to AJR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Research Ethics Committee of the Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo General Hospital, with approval number 20030331. After consideration of ethical issues, logistics and urgency of this work, the Committee waived the requirement for written individual informed consent and approved the sharing of anonymized data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.ACE-2angiotensin converting enzyme 2COVID-19Coronavirus disease 2019CTcomputed tomographyGICgastrointestinal complaintsHCAhierarchical cluster analysesIQRinterquartile rangeNIHRDNational Institutes for Health Research and DevelopmentNLRneutrophil-to-lymphocyte ratioPCAprincipal component analysesRT-PCRreal time polymerase chain reactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SDstandard deviationTBlung tuberculosis